76 results
F-6 POS
ASLN
ASLAN Pharmaceuticals Ltd
14 Jun 24
Automatic registration for ADRs (post-effective amendment, foreign)
4:30pm
Limited
n/a
Each unit represents one American Depositary Share.
Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule
F-6 POS
EX-99
ASLN
ASLAN Pharmaceuticals Ltd
14 Jun 24
Automatic registration for ADRs (post-effective amendment, foreign)
4:30pm
by Holders and the Company for the purpose of communicating with Holders in the interest of the business of the Company or a matter relating to the Deposit … thereof) at any time or from time to time when deemed expedient by it. At the request of a Holder, the Depositary shall, for the purpose
F-3
ASLN
ASLAN Pharmaceuticals Ltd
12 Jun 24
Shelf registration (foreign)
4:32pm
that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than … ) available to the selling shareholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholder
6-K
EX-4.2
ASLN
ASLAN Pharmaceuticals Ltd
31 May 24
Current report (foreign)
4:25pm
purpose of acquiring this Warrant or the Shares.
4.2Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition … and irrevocably and expressly agree to submit to the jurisdiction of the courts of New York, New York, USA for the purpose of resolving any disputes
6-K
EX-99.1
ASLN
ASLAN Pharmaceuticals Ltd
22 Apr 24
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
8:29am
of the rescue medication for the purpose of efficacy analyses. Missing data were analysed using Last Observation Carried Forward imputation.
4.Least squares
424B5
jgkvpniz5gy1
12 Apr 24
Prospectus supplement for primary offering
8:15am
6-K
EX-99.1
0vd6s9p9fdo2irpy
12 Apr 24
Amendment No. 2 to the Open Market Sale Agreementsm
8:10am
S-8
y51ucxeul1ycs4x762
12 Apr 24
Registration of securities for employees
6:37am
F-3
u2rmx2om
25 Mar 24
Shelf registration (foreign)
4:46pm
424B5
w722 fl9h6gg
14 Mar 24
Prospectus supplement for primary offering
6:24am
6-K
EX-10.1
pdl83d9omnl bv
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-4.1
9dfw578e d8wy
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-99.1
ly6zkn6cy9nw7
24 Jan 24
Current report (foreign)
7:52am
6-K
EX-99.2
xm7v1tqymd4n
22 Dec 23
Current report (foreign)
4:24pm
F-6EF
EX-99
7npza1 5hv
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
F-6EF
g29ztjexbi1m1y45qk65
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm